Hikma Pharmaceuticals

Update in progress

HIK.L (LSE)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells generic, specialty, and branded medicines. It operates through three segments: Injectables, Hikma Rx, and Branded. Injectables supplies generic and specialty injectable medicines mainly to hospitals. Branded offers branded generics and in-licensed products to retail and hospital customers. Hikma Rx provides oral, respiratory, and other generics and specialty products for retail. The company serves multiple regions worldwide and is headquartered in London, founded in 1978.

Company score

Sentiment: 0.41; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: -0.01; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.52; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.07; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.17; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.29; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive